If there is a drug which you should immediately start on now, it is celecoxib (Celebrex).
Most of the NSAIDS have anticancer action, particularly the newer selective COX-2 ones.
However, celecoxib has unique and potent anticancer pathways way beyond COX-2/PGE2
- and this includes p53 and microRNAs.
This is why Celebrex is the most studied of the NSAIDS against cancer. Search Medline
with "celecoxib" and "cancer" and you will turn out some 1,400 studies. Analogs of celecoxib
have been developed in an attempt to enhance its anticancer action.
http://www.ncbi.nlm....ELECOXIB CANCERAnother potent COX-2 NSAID was the famous rofecoxib (Vioxx).
When they took out rofecoxib (Vioxx) from the market after the big public hoo-hah
about its adverse heart effects which was blown way out of proportin, they effectively
took out a potent anticancer drug.
Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an
antiangiogenic therapy of glioblastoma multiforme.http://www.ncbi.nlm....ubmed/15565458/" We found that celecoxib inhibited the proliferation of various glioblastoma cell lines
in vitro much more potently than traditional NSAIDs. In addition, although several
different selective COX-2 inhibitors potently reduced PGE2 levels in these cells,
none of them exerted anti-proliferative effects that were comparable to celecoxib.The addition of external PGE2 to celecoxib-treated cells did not restore proliferation,
indicating that growth inhibition by celecoxib was not mediated via the blockage of
PGE2 production. "
http://www.landesbio...bt/article/571/".....
celecoxib was able to exert pronounced pro-apoptotic effects in vitro and in vivo
in the absence of any apparent involvement of COX-2. In fact, newly synthesized close
structural analogs of the celecoxib molecule revealed that it was possible to separate
COX-2 inhibitory function from the ability to trigger apoptosis; for example, the analog
2,5-dimethyl-celecoxib (DMC) has lost COX-2 inhibitory function, yet exerts increased
cytotoxic potency. "
http://www.ncbi.nlm....pubmed/20879982The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth
and induces apoptosis of human glioblastoma cells via the NF-κB pathway.
http://www.ncbi.nlm....ubmed/21847707/MicroRNAs in Human Malignant Gliomas.Furthermore, miRNAs also regulate specific signaling pathways, including the
critical core pathways in glioblastoma. As a result, miRNAs have the potential to
affect the responses to molecular-targeted therapies. More recent studies have
revealed that
miRNAs might be associated with cancer stem cell properties,
affecting tumor maintenance and progression. Recent investigation have revealed
that miRNAs are not only biological markers with diagnostic implications, but also
one of the most promising treatment targets in human glioblastoma.http://www.ncbi.nlm..../pmid/22848219/Current Progress on Understanding MicroRNAs in Glioblastoma Multiforme.
http://www.ncbi.nlm....pubmed/22893786MicroRNA targeting as a therapeutic strategy against glioma.http://www.ncbi.nlm....pubmed/22934848microRNA expression pattern and its alteration following celecoxib
intervention in human colorectal cancer.
http://www.ncbi.nlm....cles/PMC3438602Cancer chemoprevention by targeting the epigenome.http://www.ncbi.nlm....pubmed/21158707COX-2 regulates the proliferation of glioma stem like cells.http://www.ncbi.nlm....pubmed/21763744Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction
of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy." Our findings reveal that p53 increases human glioblastoma sensitivity to celecoxib.
Celecoxib inhibits glioblastoma cell viability by induction of DNA damage, leading to
p53-dependent G1 cell cycle arrest and p53-dependent autophagy, but not apoptosis.http://www.molecular...m/content/8//66" Low-dose continuous temozolomide in combination with celecoxib seems
to have activity in
recurrent glioblastoma without relevant toxicity. "
Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
http://www.ncbi.nlm....pubmed/20446016Far-distant metastases along the CSF pathway of glioblastoma multiforme
during continuous low-dose chemotherapy with temozolomide and celecoxib.http://www.ncbi.nlm....pubmed/20306105
Edited by tham, 23 September 2012 - 08:35 PM.